Home   Jobs   Conferences   Fellowships   Books   Buyer's Guide   Feature Page



Advertisement
Advertisement





14 April 2014: NovoPath announces a customizable web portal to its NovoPath anatomic pathology laboratory information system (APLIS), helping customers efficiently comply with new legislation requiring labs to provide direct patient access to reports. The new feature enables patients with test results to log on to a web portal through a lab's website and download the documents generated through NovoPath's APLIS.

The patient access law, recently enacted by the Department of Health and Human Services (HHS), requires laboratories to provide patients, or their designated representatives, access to completed test results without requiring their physician's approval or the resulting laboratory. The new rule also eliminates the exception under HIPAA of CLIA-certified or CLIA-exempt laboratories to provide reports. Patients also can continue to obtain lab test reports from the ordering clinician.

The NovoPath Web Portal meets the highest commercially available security standards, alleviating the need to maintain handwritten logs, delivery receipts and other forms of manual tracking.

For more information, visit novopath.com.







28 March 2014: Datacolor® recently announced the launch in the U.S. of Datacolor CHROMACAL™, a first-of-its-kind system that enables scientists to establish and preserve the color integrity of their digital transmitted brightfield microscopy images. The system is available for sale through EMS (Electron Microscopy Sciences, Hatfield, PA), the exclusive distributor of Datacolor CHROMACAL in the United States.

"With the assortment of microscope equipment and image capture/processing software available today, scientists are faced with an ever-expanding challenge of achieving color consistency of digital images," said Albert Busch, President and CEO for Datacolor. "To date, there has been no standardized solution to address this need. With CHROMACAL, we developed a reliable, easy-to-use, and integrated system for achieving digital color integrity in brightfield microscopy."

For further information on Datacolor CHROMACAL, click here.







25 March 2014: Bio SB, along with partner ZytoVision, announce 9 new ISH probes for use in cancer diagnostics:

New Fluorescent Probes (FISH)

• ZytoLight SPEC VHL/1p12/CEN7/17 Quadruple Color Probe (Renal Cell Carcinoma)
• ZytoLight SPEC CCND1 Break Apart/2q11/CEN 6 Quadruple color probe (Renal Cell Carcinoma)
• ZytoLight SPEC ETV1/CEN 7 Dual Color Probe (Melanoma)
• ZytoLight SPEC NTRK1 Dual Color Probe (Papillary Thyroid Carcinoma)
• ZytoLight SPEC FGFR1 Dual Color Probe (Leukemia/Lymphoma)
• ZytoLight SPEC FGFR2 Dual Color Probe (Solid Tumor)
• ZytoLight SPEC FGFR3 Dual Color Probe (Multiple Applications)
• ZytoLight SPEC BCL2/CEN18 Dual Color Probe (Lymphoma)

New Chromogenic Probes (CISH)

• ZytoDot 2C SPEC FUS Break Apart Probe (Liposarcoma)

For more information, click here.






13 March 2014: University of Michigan MLabs now offers two new FISH assays for TFEB and TFE3 rearrangements. The primary value of these assays is in accurate diagnosis of a subset of uncommon renal tumors referred to as translocation-associated renal cell carcinomas (tRCC). Translocation-associated renal cell carcinomas tend to occur in children or young adults and are associated with a poor prognosis (especially in adults). Two main classes of tRCC are currently identified: translocations involving the TFE3 locus on chromosome Xp11 and a t(6;11) translocation generating the TFEB gene fusion.

These renal tumors can be morphologically challenging without the aid of ancillary studies. Whereas IHC for TFE3 or TFEB or their common transcriptional target, cathepsin K, is specific for tRCC, there is poor reproducibility of TFE3 or TFEB IHC and the sensitivity is still not high enough to exclude the possibility of false-negative results. FISH, however, has been clearly documented for the diagnosis of these renal tumors and exhibits a high degree of sensitivity and specificity. FISH for TFE3 and TFEB gene fusions is now offered as one of the clinical assays at University of Michigan Health Systems. This TFE3 FISH assay can also be used to confirm the diagnosis of alveolar soft part sarcoma if needed/indicated.

For more information, contact MLabs at 800-862-7284, or visit us online at www.mlabs.umich.edu.





13 March 2014: An international panel of leaders in the pathology community announced its support of four principles designed to drive positive change and improve patient safety in the anatomic pathology laboratory. The "Principles for Pathology and Patient Safety" address key issues where the expressed need for standardization and solutions is most acute.

At the invitation of Ventana Medical Systems, Inc., a member of the Roche Group, the panel recently convened to examine the state of lab-based patient safety, with the challenge to work toward a consensus on how to advance the standard of care for patients. The group, known as the International Pathology Patient Safety Advisory Board, concluded its work with this shared vision:

1. All patients around the globe deserve standardized, high quality pathology services.
2. As patient advocates, to support accurate diagnosis and enable personalized medicine, the International Pathology Patient Safety Advisory Board identifies significant opportunities to improve patient safety by developing and implementing solutions to enhance:
• tissue preservation
• specimen/slide identification and tracking; and
• prevention of tissue contamination
3. We, the members of the International Pathology Patient Safety Advisory Board, find further opportunity to define standardized parameters for data collection and sharing in the assessment of these processes leading to quality measures for laboratory improvement.
4. We call upon the pathology profession to collaborate with laboratory and hospital administrative partners, clinician colleagues, and the laboratory diagnostics industry to address these opportunities to achieve excellence in patient care.

For more information, click here.




2 March 2014: PerkinElmer announces its Lamina multilabel slide scanner, which delivers clear, high resolution images from whole-slides and Tissue Microarrays (TMAs). With both brightfield and fluorescence modes in one instrument, Lamina is a flexible platform for your research pathology lab. The Lamina addresses your everyday H&E needs as well as immunohistochemistry (IHC) and immunofluorescence. With the option of selecting our new proprietary Autofluorescence Reduction technology and crosstalk correction between fluorophores, it produces exceptional results to enable clearer visualization of protein expression in formalin-fixed paraffin-embedded (FFPE) tissues. Visit www.perkinelmer.com to learn more.





28 February 2014: How to Share Pathology's Value: Free CAP Webinar, March 17, 2014, Noon-1:00 pm (CT). Register now to learn practical specifics that demonstrate the valuable role of the pathologist and the laboratory as the starting point for integrated care delivery, quality, and cost control.





25 February 2014: Photodyne Technologies is pleased to offer their new line of grossing macrophotography units. The P series units are available with off the shelf Point and Shoot cameras or with top of the line DSLR cameras with 18 MP resolution allowing RAW data manipulation. These new units incorporate low DC voltage operation for enhanced safety and with all LED bulbs for cool and more efficient performance. Model 701-P is a full size console and model 702-P is a desk top model, both with 30 by 20 photographing area. Model 703-P is a smaller footprint unit with 20 by 13 photographing surface area. Prices for the new units start at $6725 for model 701-P, $5975 for model 702-P, and $5575 for model 703-P.


For more information, visit us online at www.photodyne.com, or contact us at 800-660-2147 or hrzc@earthlink.net.





21 February 2014: Mopec introduces the FD500, our Formalin Dispensing Station. Constructed of all stainless steel, it features a 7.5" W x 9" deep sink. Three grid plates are provided (one sink and two perforated). Additional standard features include: GFCI, fluorescent lighting, high low alarm lights, adjustable shelf, bi-parting lexan doors, lexan side splash shield and leveling pads.


FD500

For more information call 800-362-8491, email info@mopec.com or visit www.MOPEC.com.







29 January 2014: As the diagnostics market continues to grow, researchers and clinicians have a greater need for a wide variety of high quality and cost effective control slides. Control slides are invaluable tools utilized by institutions when validating reagents, qualifying new products, testing protocols or performing research which requires multiple tissue types. Bio SB control slides are cost effective, high quality tissues mounted on Hydrophilic Plus slides which are validated for use in immunohistochemical (IHC) and in situ hybridization (ISH) applications.

The Normal Human Tissue Micro Array, or NH-TMA, is an excellent way to test an antibody, ISH probe or other reagent on multiple tissues. Bio SB NH-TMA arrays are available in both 11 or 23-core configurations. Bio SB NH-TMA's are an excellent way for clinics and research labs to save time and money by allowing multiple tissues to be tested on one slide. All TMA’s have been validated using immunohistochemical methods and are positive for over 100 antibodies. Additionally all TMA's can be custom ordered to be cut and placed on any slide including the Bio SB Hydrophilic Plus slide.

For more information, click here.






8 January 2014: Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announces the VENTANA HER2/neu (4B5) Rabbit Monoclonal Primary Antibody assay as a companion diagnostic for detecting HER2 protein expression for patients who, in countries where they are approved, may be appropriate candidates for Perjeta® (pertuzumab) and Kadcyla™ (ado-trastuzumab emtansine). Previously, the VENTANA HER2 (4B5) test was labeled only for the identification of HER2-positive breast and gastric cancer patients for whom Herceptin® (trastuzumab) treatment is being considered.

For more than a decade, Herceptin (trastuzumab), a HER2-directed therapy, has been approved by health authorities for people with HER2-positive breast cancer. To further help build on the progress made with Herceptin, Roche has recently introduced two additional HER2-directed therapies, Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine). Perjeta® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel chemotherapy in people with HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic disease.

Kadcyla™ (ado-trastuzumab emtansine) is approved for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin® (trastuzumab) and a taxane chemotherapy. People should either have already been treated for their metastatic cancer or have had their early-stage cancer come back during or within six months after they completed a course of treatment following surgery.

Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2+ and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high risk feature.


Breast carcinoma HER2 (4B5) positive, Score: 3+ Magnification: 40X

For more information, click here.





26 August 2013: PerkinElmer and Advanced Cell Diagnostics (ACD) have entered a co-marketing agreement to develop joint applications for the visualization of multiplexed fluorescence RNA biomarkers in situ, in formalin-fixed paraffin-embedded tissues. In the past, it was not possible to detect and quantify RNA in situ in these samples due to lack of sensitivity and specificity of labels within highly autofluorescent tissues.

Click here for more information.





21 August 2013: Aperio ePathology, a leader in providing global pathology solutions, has digitized over 550 slides of Einstein’s brain enabling researchers, scientists and enthusiasts around the world to view the original slides prepared by Dr. Thomas Harvey, the pathologist who conducted the autopsy of Albert Einstein in 1955. The remarkable collection of slides was donated to the National Museum of Health and Medicine in Silver Spring, MD after the pathologist's death. The Einstein Brain Atlas app for iPad has been developed to allow neuroscientists, researchers, educators and others interested in science to explore sections of the Nobel Prize-winning physicist’s brain in microscopic detail. For more information, click here.






3 July 2013: Milestone introduces the BoneSTATION, a dedicated system for standardization of fixation and decalcification of bone specimens. Optimize molecular testing results with increased RNA yield from routine cases by combining less aggressive decalcifying solutions with the BoneSTATION's controlled agitation and temperature management. Users can access and build time-saving protocols through a touch screen icon driven interface, which also enables temperature control and monitoring.

Space restricted laboratories will appreciate the BoneSTATION's small footprint. Two work platforms, one for decalcification, contains a stirring heating plate paired with an infrared sensor for precise temperature control. The second platform contains the fixation area, which maintains homogeneous reagent temperatures with an integrated magnetic stirrer. Also, an included glass "workbench" provides users with an area to assess specimen quality.



For more information, call 866-995-5300, email info@milestonemed.com or visit www.milestonemed.com.





12 June 2013: HANSEL Stain has been the recommended in-vitro diagnostic stain for the identification of eosinophils in secretions for many years. Please see our product summary on Pathology Outlines here.

Lide Laboratories also offers other diagnostics stains including our new Urine Sediment Stain and Tinea Test Stain. Our concentrated Urine Sediment Stain combines Crystal Violet (0.1%), Ammonium Oxalate (0.03%) and Safranin O (0.25%) with the base formula used in HANSEL Stain. Our Tinea Test Stain [Lactophenol Cotton (Aniline) Blue (0.05%)] is formulated for the microscopic examination of fungi.

Please see our web page for more information: www.lidelabs.com/diagnosticstains.html. New customers can send us a request for free samples on our Contact Us web page.






14 April 2013: PSA is pleased to announce that we are now part of McKesson. This combined organization brings together an extensive portfolio of services and we are now better positioned to help our customers choose from a broader set of services from practice and revenue cycle management to coding, marketing and networking capabilities.

To learn more, visit www.McKesson.com/pathologyservices, or contact Leigh Polk at Leigh.Polk@McKesson.com.





13 October 2012: Introducing EXAKT’s NEW Pathology Saw. Designed specifically for pathology lab use, this bone saw offers the SAFEST alternative for grossing samples. Unlike butcher saws used in many labs, the diamond band of the EXAKT saw does not cut, but grinds the bone very precisely. There is no immediate risk of injury to the technician if the band is touched unintentionally. The EXAKT 312 Diamond Pathology Saw easily cuts metal implants or screws encountered during the grossing process, without destroying the sample. Even very small specimens can be cut safely and precisely! Visit www.exaktusa.com/pathology-saw and watch the EXAKT Pathology Saw Video.







11 November 2011: bioTheranostics, Inc., a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, announces a clinical study that links CancerTYPE ID® molecular testing with improved patient outcome. Patients in which CancerTYPE ID predicted a colorectal site of origin that subsequently received site-specific therapy had a median survival three times that of what has been reported in patients treated empirically for cancer of unknown primary (CUP). These results make CancerTYPE ID the only marketed molecular cancer classifier to demonstrate therapeutic response and patient benefit based on molecular tumor profiling.

The study, led by John Hainsworth, MD, of the Sarah Canon Research Institute, A Retrospective Study of Treatment Outcomes in Patients with Carcinoma of Unknown Primary Site and a Colorectal Cancer Molecular Profile (Clin Colorectal Cancer 2011 Oct 13 [Epub ahead of print]), focused on the improved treatment response and survival in a group of patients in which CancerTYPE ID results were utilized in the selection of site-specific therapy. According to the study findings, which will be published in the December issue of Clinical Colorectal Cancer and currently are available online, 75 percent of the patients showed negative colonoscopy results, and approximately half the patients had atypical immunohistochemistry for colorectal cancer. Significantly, CancerTYPE ID was used as part of the routine work-up and site-specific treatment was selected based on the molecular assay prediction.

The study results demonstrated a 50 percent response rate in patients treated with first-line regimens for colorectal cancer versus only 17 percent in patients treated with current empiric therapies for CUP (P value = 0.0257). Patients predicted to have colorectal cancer by CancerTYPE ID and treated with colorectal cancer treatment regimens experienced a median survival of 27 months. In comparison, patients treated with empiric CUP treatment have historical median survivals ranging from 8 to 11 months.

For more information please contact Wendy Johnson, Associate Director Marketing, bioTheranostics, 858-587-5887 or click here.






26 July 2011: OPTRONICS presents a case study about High Definition Hematology. In 2009, the Royal Berkshire Hospital (RBH) made the decision to update its microscope camera system. Located in the Haematology Department, the equipment originally consisted of a microscope mounted analogue video camera connected to a 21-inch professional monitor. This was used for presentations and training purposes for over ten years until it started to fail and display picture defects. Click here to read the short article.

For more information, contact Rich Crandall, Director of Business Development at 805.562.3980 or rcrandall@optronics.com, or visit us online at http://www.optronics.com.






29 April 2011: An article in the January 2011 CAP Today discussed Voicebrook’s leadership in the Pathology speech recognition arena. The article focuses on the role of speech recognition software for laboratory transcription, and indicates that Voicebrook’s VoiceOver software is the only speech recognition product that is designed for pathologists. Features important for Pathologists include advanced templating, discrete data entry and CAP Cancer protocols, a knowledge base of Pathology templates, hands-free microphone and foot pedal integration, delegated and digital dictation workflows, custom integration with over 16 AP/LIS products, downtime procedures, integration with Digital Imaging platforms, and customized vocabulary and functionality to handle unique Pathology reporting workflows.

For more information, please visit http://www.voicebrook.com or click here to read the article.






26 January 2011: ARUP’s Online Scientific Resource for Research and Education provides more than 20 free CME courses for physicians. Course topics reflect current issues and developments in pathology; new courses are added monthly. This resource is provided by ARUP’s medical directors, who are faculty at the University of Utah School of Medicine, along with other highly qualified expert contributors.

The University of Utah School of Medicine designates these educational activities for AMA PRA Category 1 credit(s) and affirms that they meet the criteria for Self-Assessment Modules (SAM) credit to apply toward the Maintenance of Certification (MOC) by the American Board of Pathology.

For more information, click here.


 

 

 

10 February 2009:  Vachette Pathology is proud to announce its newly improved website Vachettepathology.com. The website will have more content and more information. The goal of the website will be to concentrate all the knowledge and experience we have into a single database that is more useable for both our current and potential customers.

 

Vachette Pathology is a practice management firm that specializes in pathology. Currently we work with over 450 pathologists nationwide and are commonly held as the industry leaders in the business of pathology and laboratory management.

 

If you have any questions or for further information, please contact Mick Raich toll free at 866-407-0763, or email mraich@vachettepathology.com




End of New Products and Services page



Advertisement